1. Home
  2. MLYS vs CCNE Comparison

MLYS vs CCNE Comparison

Compare MLYS & CCNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • CCNE
  • Stock Information
  • Founded
  • MLYS 2019
  • CCNE 1865
  • Country
  • MLYS United States
  • CCNE United States
  • Employees
  • MLYS N/A
  • CCNE N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • CCNE Major Banks
  • Sector
  • MLYS Health Care
  • CCNE Finance
  • Exchange
  • MLYS Nasdaq
  • CCNE Nasdaq
  • Market Cap
  • MLYS 1.0B
  • CCNE 455.3M
  • IPO Year
  • MLYS 2023
  • CCNE N/A
  • Fundamental
  • Price
  • MLYS $14.30
  • CCNE $24.00
  • Analyst Decision
  • MLYS Strong Buy
  • CCNE Hold
  • Analyst Count
  • MLYS 4
  • CCNE 1
  • Target Price
  • MLYS $27.00
  • CCNE $25.00
  • AVG Volume (30 Days)
  • MLYS 871.8K
  • CCNE 63.6K
  • Earning Date
  • MLYS 08-12-2025
  • CCNE 07-17-2025
  • Dividend Yield
  • MLYS N/A
  • CCNE 3.04%
  • EPS Growth
  • MLYS N/A
  • CCNE N/A
  • EPS
  • MLYS N/A
  • CCNE 2.34
  • Revenue
  • MLYS N/A
  • CCNE $219,886,000.00
  • Revenue This Year
  • MLYS N/A
  • CCNE $17.91
  • Revenue Next Year
  • MLYS N/A
  • CCNE $27.71
  • P/E Ratio
  • MLYS N/A
  • CCNE $10.13
  • Revenue Growth
  • MLYS N/A
  • CCNE 1.97
  • 52 Week Low
  • MLYS $8.24
  • CCNE $18.90
  • 52 Week High
  • MLYS $18.38
  • CCNE $29.29
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 48.08
  • CCNE 70.44
  • Support Level
  • MLYS $13.22
  • CCNE $22.30
  • Resistance Level
  • MLYS $14.35
  • CCNE $23.16
  • Average True Range (ATR)
  • MLYS 0.76
  • CCNE 0.57
  • MACD
  • MLYS -0.04
  • CCNE 0.21
  • Stochastic Oscillator
  • MLYS 51.92
  • CCNE 96.62

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About CCNE CNB Financial Corporation

CNB Financial Corp is providing integrated financial solutions, which create value for both consumers and businesses. These solutions encompass deposit accounts, private banking, real estate, commercial, industrial, residential and consumer loans and lines of credit, credit cards, treasury services, online banking, mobile banking, merchant credit card processing, remote deposit and accounts receivable handling. It derives revenue through the operations as a full-service bank engaging in a full range of banking activities and services, including trust and wealth management services, for individual, business, governmental, and institutional customers. The company branch are located in Pennsylvania, Ohio, New York and Virginia.

Share on Social Networks: